Ann: Two more PANCOSIL Trial treatments using OncoSil device, page-80

First 80 Last

Share
Profile

Follow
Gekkowolf

2,589 Posts.

257

01/05/24

16:41

Post #: 73613244
Share

Originally posted by tinyteddy: ↑

I think it will have enough cash (after tomorrow) for: the percutaneous trial (20 patients), to finish the current folfirinox study, to complete FDA application process for cholangio and to retry the TGA.

The GBA application isn't requiring cash and is meant to be cash flow positive if they get it (as opposed to the above which require company funding).

Of course they want commercial agreements and they have implemented quite a few. The more sales the less pressure on the company to raise capital. But they haven't given guidance on expected sales as yet. I'm not saying they don;t need sales, they obviously do. But the other things they are doing are very valuable

Expand

So if they can manage to break even with sales let’s say then they would be in a position of strength when negotiating a buy out.

The problem I guess is that they would need to generate hundreds of sales to break even rather than single digits like they have been.

OSL Price at posting: 0.5¢ Sentiment: Hold Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

PAR

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

OCC

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

First 80 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $1.11		Change -0.125(10.2%)		Mkt cap ! $15.71M

Open	High	Low	Value	Volume
$1.25	$1.25	$1.11	$37.21K	30.57K

Buyers (Bids)

No.	Vol.	Price($)
1	8422	$1.16

Sellers (Offers)

Price($)	Vol.	No.
$1.18	587	1

View Market Depth

No.	Vol.	Price($)
1	10000	1.150
1	13995	1.085
1	7500	1.080
2	19761	1.050
1	2500	1.030

Price($)	Vol.	No.
1.180	587	1
1.195	637	1
1.200	11885	3
1.245	2418	1
1.250	46027	1

Last trade - 12.36pm 27/06/2025 (20 minute delay)

OSL (ASX) Chart

Ann: Two more PANCOSIL Trial treatments using OncoSil device, page-80

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Australia’s gas crisis is here – and dying coal plants aren’t helping

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Two more PANCOSIL Trial treatments using OncoSil device, page-80

Top Stories

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Australia’s gas crisis is here – and dying coal plants aren’t helping

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News